Peptide Comparison
Natriuretic Peptide (ANP)vsUlaritide
Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.
A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.
At a Glance
Quick
comparison
Dose Range
Natriuretic Peptide (ANP)
0.025–0.050 mcg/kg/min
Ularitide
15–15 ng/kg/min
Frequency
Natriuretic Peptide (ANP)
Once daily
Ularitide
Once daily
Administration
Natriuretic Peptide (ANP)
Intravenous infusion (continuous) - standard hospital delivery method
Ularitide
Intravenous infusion
Cycle Length
Natriuretic Peptide (ANP)
Ongoing/indefinite
Ularitide
Ongoing/indefinite
Onset Speed
Natriuretic Peptide (ANP)
Moderate (1-2 weeks)
Ularitide
Moderate (1-2 weeks)
Evidence Level
Natriuretic Peptide (ANP)
Moderate human trials (Phase 1-2)
Ularitide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Acute Fluid Management
Hemodynamic Stabilization
Symptom Relief
Cardiovascular Support
Fluid & Electrolyte Balance
Kidney Protection
Technical Data
Compound
specifications
Natriuretic Peptide (ANP)
Molecular Formula
C127H203N45O39S3
Molecular Weight
3080.5 g/mol
Half-Life
Approximately 15-30 minutes (IV administration)
Bioavailability
100% (intravenous administration)
CAS Number
Variable depending on salt form; carperitide CAS: 120399-20-4
Ularitide
Molecular Formula
C145H234N52O44S3
Molecular Weight
3505.9
Half-Life
6-7 minutes (in circulation)
Bioavailability
100% (intravenous administration)
CAS Number
Not publicly assigned (proprietary compound)
Protocols
Dosing
tiers
Natriuretic Peptide (ANP)
Ularitide
Applications
Best
suited for
Natriuretic Peptide (ANP)
Managing acute decompensated heart failure with fluid overload
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving shortness of breath caused by pulmonary congestion
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lowering elevated blood pressure in emergency cardiac situations
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing the workload on the heart during acute episodes
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ularitide
Managing acute heart failure symptoms and fluid overload
Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving oxygen delivery when your heart can't pump efficiently
Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting kidney function in critical heart patients
Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Natriuretic Peptide (ANP)
Common
- Mild discomfort at treatment site
- Hypotension (excessively low blood pressure) requiring close monitoring
- Headache and dizziness from sudden blood pressure changes
- Weakness and fatigue during or shortly after treatment
- Nausea and gastrointestinal discomfort
- Decreased kidney function temporarily, requiring follow-up monitoring
- Tremors or shaking sensations
- Atrial fibrillation (irregular heartbeat) in some patients
- Abdominal pain
- Injection site reactions if administered intravenously
- Renal dysfunction with prolonged use, especially in elderly patients
Serious
- Severe allergic reaction
Ularitide
Common
- Dizziness or lightheadedness
- Low blood pressure (hypotension)
- Headache
- Nausea
Uncommon
- Elevated potassium levels
- Worsening kidney function (transient)
- Allergic reactions at injection site
- Chest discomfort
- Irregular heartbeat (arrhythmia)
Serious
- Severe hypotension requiring intervention
- Worsening heart function in some patients
- Acute kidney injury (rare)
- Anaphylactic shock (very rare)
Research Status
Safety
& evidence
Natriuretic Peptide (ANP)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion requires periodic treatment breaks or dose adjustments.
Contraindications
- xSevere kidney failure with very low glomerular filtration rate
- xRecent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
- xAcute coronary syndrome or recent heart attack where vasodilation could be harmful
- xSevere hypotension or cardiogenic shock without proper supportive care
- xAllergies to ANP, carperitide, or any components of the pharmaceutical formulation
Ularitide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Not FDA approved
Safety Overview
Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. Natriuretic peptide class risks include worsening renal function in some patients and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.
Contraindications
- xHypotension (dangerously low blood pressure)
- xCardiogenic shock without proper monitoring
- xSevere renal dysfunction in some cases
- xAllergy to synthetic peptides
Decision Guide
Which is
right for you?
Choose Natriuretic Peptide (ANP) if...
- Managing acute decompensated heart failure with fluid overload
- Relieving shortness of breath caused by pulmonary congestion
- Lowering elevated blood pressure in emergency cardiac situations
- Reducing the workload on the heart during acute episodes
Choose Ularitide if...
- Managing acute heart failure symptoms and fluid overload
- Improving oxygen delivery when your heart can't pump efficiently
- Protecting kidney function in critical heart patients